Scarica l'app Stockscreener
3.75
0.13%
-0.00
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ABCL Giù?
Forum
Previsione
Abcellera Biologics Inc Borsa (ABCL) Ultime notizie
AbCellera shareholders approve board election and auditor - Investing.com Australia
AbCellera shareholders approve board election and auditor By Investing.com - Investing.com Nigeria
AbCellera Biologics Holds Annual Shareholder Meeting - TipRanks
AbCellera Biologics: The Dilemma Of A Promising Pipeline Alongside Cash Burn (ABCL) - Seeking Alpha
ABCELLERA BIOLG (ABCL) Upgraded to Buy: Here's Why - MSN
AbCellera Biologics (ABCL) Stands Out in Active Option Classes | - GuruFocus
AbCellera Biologics (ABCL) Stands Out in Active Option Classes | ABCL Stock News - GuruFocus
AbCellera Biologics Inc. (ABCL): A Bull Case Theory - MSN
Squarepoint Ops LLC Acquires 44,367 Shares of AbCellera Biologics Inc. (NASDAQ:ABCL) - Defense World
AbCellera Biologics Inc. (ABCL) Approved to Begin ABCL575 Trial for Atopic Dermatitis - MSN
AbCellera Biologics And 2 Other Promising Penny Stocks To Watch - Yahoo Finance
Why AbCellera Biologics Stock Raced Nearly 6% Higher Today - AOL.com
AbCellera (ABCL) Stock Rises on Health Canada Approval - GuruFocus
AbCellera gains Health Canada nod for AD antibody trial By Investing.com - Investing.com South Africa
AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 - BioSpace
AbCellera (ABCL) Gains Health Canada Approval for Clinical Trial - GuruFocus
AbCellera Biologics Receives Health Canada Approval for Trial - TipRanks
AbCellera Biologics Gets Health Canada Authorization for Phase 1 Trial of Dermatitis Treatment - marketscreener.com
AbCellera Receives Authorization from Health Canada to Initiate - GuruFocus
AbCellera Receives Authorization from Health Canada to Initiate a Phase 1 Clinical Trial of ABCL575 | ABCL Stock News - GuruFocus
AbCellera receives Health Canada authorization to initiate ABCL575 Phase 1 trial - TipRanks
AbCellera gains Health Canada nod for AD antibody trial - Investing.com
Health Canada Greenlights AbCellera's Novel Antibody Trial for Chronic Skin Disease Treatment - Stock Titan
AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Holdings Boosted by Millennium Management LLC - Defense World
AbCellera Biologics Inc. (ABCL): Analysts See 474% Upside Potential - MSN
AbCellera Biologics Inc. raises US$100M in series A2 financing - McCarthy Tétrault
13 Best Multibagger Stocks to Invest in Now - Insider Monkey
Truist Financial Has Lowered Expectations for AbCellera Biologics (NASDAQ:ABCL) Stock Price - Defense World
Truist cuts AbCellera stock target to $10, maintains Buy By Investing.com - Investing.com South Africa
Truist Securities Lowers Price Target for AbCellera Biologics (A - GuruFocus
Truist cuts AbCellera stock target to $10, maintains Buy - Investing.com Australia
Truist Securities Lowers Price Target for AbCellera Biologics (ABCL) | ABCL Stock News - GuruFocus
Truist Adjusts Price Target for AbCellera (ABCL) Amid Strategic Shift | ABCL Stock News - GuruFocus
Abcellera gains Canadian clearance for phase I study of ABCL-635 for vasomotor symptoms in menopause - BioWorld MedTech
Some Analysts Just Cut Their AbCellera Biologics Inc. (NASDAQ:ABCL) Estimates - simplywall.st
Analyst Forecasts Just Became More Bearish On AbCellera Biologics Inc. (NASDAQ:ABCL) - Yahoo Finance
AbCellera to begin Phase 1 trial for menopause treatment By Investing.com - Investing.com Nigeria
AbCellera Receives Authorization from Health Canada to Initiate the Phase 1 Clinical Trial of ABCL635 for Vasomotor Symptoms Due to Menopause - BioSpace
AbCellera Biologics Gets Health Canada Approval for Phase 1 Trial of Menopause Treatment - marketscreener.com
AbCellera to begin Phase 1 trial for menopause treatment - Investing.com
AbCellera (ABCL) Set to Launch Clinical Trial for Menopause Trea - GuruFocus
AbCellera (ABCL) Set to Launch Clinical Trial for Menopause Treatment | ABCL Stock News - GuruFocus
0.34%
7.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):